切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2025, Vol. 15 ›› Issue (01) : 95 -100. doi: 10.3877/cma.j.issn.2095-3232.2026.01.015

临床研究

非酒精性脂肪性肝病相关肝癌的临床诊治单中心分析
沈宏年1,2, 陆含笑1,2, 张硕1,2, 姜东林3, 向文1,2, 项洁4, 杨军1,2,()   
  1. 1 214122 江苏省无锡市,江南大学附属医院肝胆外科
    2 214122 江苏省无锡市,江南大学无锡医学院
    3 214122 江苏省无锡市,无锡肝胆外科研究所
    4 214122 江苏省无锡市,无锡市康复医院
  • 收稿日期:2025-07-20 出版日期:2025-02-10
  • 通信作者: 杨军
  • 基金资助:
    无锡市医疗卫生双百拔尖人才(BJ2023049)

Clinical diagnosis and treatment of nonalcoholic fatty liver disease-associated hepatocellular carcinoma: a single-center analysis

Hongnian Shen1,2, Hanxiao Lu1,2, Shuo Zhang1,2, Donglin Jiang3, Wen Xiang1,2, Jie Xiang4, Jun Yang1,2,()   

  1. 1 Department of Hepatobiliary Surgery, Affiliated Hospital of Jiangnan University, Wuxi 214122, China
    2 Wuxi Medical College of Jiangnan University, Wuxi 214122, China
    3 Wuxi Institute of Hepatobiliary Surgery, Wuxi 214122, China
    4 Wuxi Rahabilitation Hospital, Wuxi 214122, China
  • Received:2025-07-20 Published:2025-02-10
  • Corresponding author: Jun Yang
引用本文:

沈宏年, 陆含笑, 张硕, 姜东林, 向文, 项洁, 杨军. 非酒精性脂肪性肝病相关肝癌的临床诊治单中心分析[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 15(01): 95-100.

Hongnian Shen, Hanxiao Lu, Shuo Zhang, Donglin Jiang, Wen Xiang, Jie Xiang, Jun Yang. Clinical diagnosis and treatment of nonalcoholic fatty liver disease-associated hepatocellular carcinoma: a single-center analysis[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 15(01): 95-100.

目的

探讨单中心非酒精性脂肪性肝病(NAFLD)相关肝细胞癌(HCC)患者的临床病理学特征。

方法

回顾性分析2020年1月至2024年10月江南大学附属医院收治的10例NAFLD相关HCC患者临床病理学资料。其中男7例,女3例;年龄44~80岁,中位年龄71岁。所有患者均签署知情同意书,符合医学伦理学规定。分析其病史、实验室检查、影像学特点、治疗方式及预后。

结果

10例患者中7例为体检发现肝脏占位,临床无明显症状;1例为无明显诱因的上腹痛伴发热,2例患者为无明显诱因的上腹痛伴黄疸。10例患者既往均有脂肪肝病史,均无乙肝和丙肝病史,无过量饮酒史,其中1例轻度脂肪肝,4例中度脂肪肝,5例重度脂肪肝。4例患者合并AFP升高,最高者3 000 μg/L。其中4例单纯性高血压,2例高血压合并糖尿病,1例高血压合并脑梗死。2例患者术前影像学诊断为肝血管瘤,2例术前影像学诊断为不典型良性肿瘤。7例患者均行腹腔镜肝癌根治术治疗。术后病理学检查示高分化型1例、中高分化型2例、中分化型3例、中低分化型1例,低分化型3例。术后1例出现胆漏,其余恢复顺利。住院时间为(14±4) d。随访3个月至2年,除1例患者复发外,其余患者均无复发。

结论

NAFLD相关HCC患者常常伴随有脂肪肝,对于合并有肝脏占位的NAFLD患者,应考虑到肝癌的可能,需密切观察,定期复查,一旦确诊应及时早期手术治疗。

Objective

To investigate the clinicopathological features of non-alcoholic fatty liver disease (NAFLD)-associated hepatocellular carcinoma (HCC) in a single center.

Methods

Clinicopathological data of 10 patients with NAFLD-associated HCC admitted to Department of Hepatobiliary Surgery, Affiliated Hospital of Jiangnan University from January 2020 to October 2024 were retrospectively analyzed. Among them, 7 patients were male and 3 female, aged from 44 to 80 years, with a median age of 71 years. The informed consents of all patients were obtained and the local ethical committee approval was received. Medical history, laboratory examination, imaging features, treatment methods and clinical prognosis were analyzed.

Results

Among 10 patients, 7 cases were diagnosed with liver space-occupying lesions by physical examination, and no evident clinical symptoms were detected. One patient developed the upper abdominal pain accompanied with fever of unknown origin, and two patients had the upper abdominal pain complicated with jaundice of unknown origin. All 10 patients had a history of fatty liver disease, neither hepatitis B, hepatitis C nor excessive drinking, including 1 case of mild fatty liver disease, 4 moderate fatty liver disease and 5 severe fatty liver disease, respectively. Four patients were complicated with elevated AFP, highest up to 3 000 μg/L. Among them, 4 patients were diagnosed with hypertension, 2 cases of hypertension complicated with diabetes mellitus, 1 case of hypertension complicated with cerebral infarction. Preoperative imaging revealed two patients were diagnosed with hepatic hemangioma, and 2 cases of atypical benign tumors. All 7 patients underwent laparoscopic radical resection of HCC. Postoperative pathological examination showed 1 case of well-differentiated HCC, 2 moderately-and well-differentiated HCC, 3 moderately-differentiated HCC, 1 moderately-and poorly-differentiated HCC and 3 poorly-differentiated HCC, respectively. One case experienced postoperative bile leakage, and the remaining patients were recovered. The length of hospital stay was (14±4) d. Follow-up endured for 3 months to 2 years. Only 1 patient recurred.

Conclusions

NAFLD-associated HCC patients are primarily complicated with fatty liver disease. For NAFLD patients complicated with liver masses, the possibility of liver cancer should be considered. Intimate observation and regular reexamination are needed. Prompt surgical treatment should be performed upon diagnosis.

表1 十例NAFLD相关HCC患者临床特征
图1 一例NAFLD相关HCC患者腹部CT检查 注:a为CT平扫示肝脏密度显著降低,肝血管分支显示不清,左外叶肝脏肿瘤与脂肪肝组织密度相似;b为增强CT动脉期,红色箭头显示肝脏肿瘤轻度强化,难于与不典型血管瘤鉴别;c为门静脉期肝内血管清晰可见,走行自然,肝脏左外叶肿瘤呈延迟性强化;NAFLD为非酒精性脂肪性肝病
表2 十例NAFLD相关HCC患者治疗情况
图2 NAFLD相关HCC的病理表现 注:中分化HCC,周围肝组织中度脂肪变性,汇管区炎性细胞浸润(HE,×100);NAFLD为非酒精性脂肪性肝病
[1]
Byrne CD, Targher G. NAFLD: a multisystem disease[J]. J Hepatol, 2015, 62(1): S47-S64. DOI: 10.1016/j.jhep.2014.12.012.
[2]
杨金秋, 赵文霞, 周铖, 等. 非酒精性脂肪性肝病发生进展期肝纤维化的危险因素及列线图预测模型构建[J]. 临床肝胆病杂志, 2024, 40(8): 1579-1584. DOI: 12449/JCH240812.
[3]
Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84. DOI: 10.1002/hep.28431.
[4]
Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 389-398. DOI: 10.1016/S2468-1253(19)30039-1.
[5]
Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030[J]. J Hepatol, 2018, 69(4): 896-904. DOI: 10.1016/j.jhep.2018.05.036.
[6]
Zhou J, Zhou F, Wang W, et al. Epidemiological features of NAFLD from 1999 to 2018 in China[J]. Hepatology, 2020, 71(5): 1851-1864. DOI: 10.1002/hep.31150.
[7]
Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(4): 223-238. DOI: 10.1038/s41575-020-00381-6.
[8]
Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans[J]. Mol Metab, 2021, 50: 101122. DOI: 10.1016/j.molmet.2020.101122.
[9]
Han SK, Baik SK, Kim MY. Non-alcoholic fatty liver disease: definition and subtypes[J]. Clin Mol Hepatol, 2023, 29(suppl): S5-S16. DOI: 10.3350/cmh.2022.0424.
[10]
Hu N, Yan G, Tang M, et al. CT-based methods for assessment of metabolic dysfunction associated with fatty liver disease[J]. Eur Radiol Exp, 2023, 7(1): 72. DOI: 10.1186/s41747-023-00387-0.
[11]
Starekova J, Hernando D, Pickhardt PJ, et al. Quantification of liver fat content with CT and MRI: state of the art[J]. Radiology, 2021, 301(2): 250-262. DOI: 10.1148/radiol.2021204288.
[12]
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[13]
Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009[J]. Hepatology, 2015, 62(6): 1723-1730. DOI: 10.1002/hep.28123.
[14]
Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study[J]. Hepatology, 2016, 63(3): 827-838. DOI: 10.1002/hep.28368.
[15]
Stine JG, Wentworth BJ, Zimmet A, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases[J]. Aliment Pharmacol Ther, 2018, 48(7): 696-703. DOI: 10.1111/apt.14937.
[16]
Desai A, Sandhu S, Lai JP, et al. Hepatocellular carcinoma in non-cirrhotic liver: a comprehensive review[J]. World J Hepatol, 2019, 11(1): 1-18. DOI: 10.4254/wjh.v11.i1.1.
[17]
Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic steatohepatitis: a review[J]. JAMA, 2020, 323(12): 1175-1183. DOI: 10.1001/jama.2020.2298.
[18]
Parola M, Pinzani M. Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies[J]. Mol Aspects Med, 2024, 95: 101231. DOI: 10.1016/j.mam.2023.101231.
[19]
Hagström H, Tynelius P, Rasmussen F. High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1. 2 million men[J]. Gut, 2018, 67(8): 1536-1542. DOI: 10.1136/gutjnl-2016-313622.
[20]
Yang JD, Ahmed F, Mara KC, et al. Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease[J]. Hepatology, 2020, 71(3): 907-916. DOI: 10.1002/hep.30858.
[21]
Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis[J]. PLoS Med, 2014, 11(4): e1001624. DOI: 10.1371/journal.pmed.1001624.
[22]
Tincopa MA, Loomba R. Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J]. Lancet Gastroenterol Hepatol, 2023, 8(7): 660-670. DOI: 10.1016/S2468-1253(23)00066-3.
[23]
Lee YJ, Lee JM, Lee JS, et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis[J]. Radiology, 2015, 275(1): 97-109. DOI: 10.1148/radiol.14140690.
[24]
Roberts LR, Sirlin CB, Zaiem F, et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis[J]. Hepatology, 2018, 67(1): 401-421. DOI: 10.1002/hep.29487.
[25]
Kobayashi S, Matsui O, Gabata T, et al. Hemodynamics of small sclerosing hepatocellular carcinoma without fibrous capsule: evaluation with single-level dynamic CT during hepatic arteriography[J]. Abdom Imaging, 2008, 33(4): 425-427. DOI: 10.1007/s00261-007-9288-z.
[26]
Piazzolla VA, Mangia A. Noninvasive diagnosis of NAFLD and NASH[J]. Cells, 2020, 9(4): 1005. DOI: 10.3390/cells9041005.
[27]
Zhou JH, Cai JJ, She ZG, et al. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice[J]. World J Gastroenterol, 2019, 25(11): 1307-1326. DOI: 10.3748/wjg.v25.i11.1307.
[28]
Sanyal AJ, Castera L, Wong VW. Noninvasive assessment of liver fibrosis in NAFLD[J]. Clin Gastroenterol Hepatol, 2023, 21(8): 2026-2039. DOI: 10.1016/j.cgh.2023.03.042.
[29]
Foerster F, Gairing SJ, Müller L, et al. NAFLD-driven HCC: safety and efficacy of current and emerging treatment options[J]. J Hepatol, 2022, 76(2): 446-457. DOI: 10.1016/j.jhep.2021.09.007.
[30]
Wang Y, Deng B. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers[J]. Cancer Metastasis Rev, 2023, 42(3): 629-652. DOI: 10.1007/s10555-023-10084-4.
[31]
Llovet JM, De Baere T, Kulik L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(5): 293-313. DOI: 10.1038/s41575-020-00395-0.
[1] 焦瑞, 徐刚, 练慧斌, 殷志敏, 韩辉, 周杰. 骨盆骨折大出血患者动脉栓塞术后臀肌及皮肤坏死治疗方法的探讨[J/OL]. 中华损伤与修复杂志(电子版), 2026, 21(01): 7-11.
[2] 刘恒, 何亦龙, 袁蕊, 刘燕燕, 卢帅, 公茂琪, 查晔军, 蒋协远. 免疫与基质调节细胞治疗创伤性异位骨化的实验研究[J/OL]. 中华损伤与修复杂志(电子版), 2026, 21(01): 47-53.
[3] 何林霞, 相阳, 刘心如, 郑兴锋. 巨噬细胞代谢重编程在脓毒症急性肺损伤中作用的研究进展[J/OL]. 中华损伤与修复杂志(电子版), 2026, 21(01): 69-74.
[4] 杨一辰, 廖习成, 马玥麟, 李迎, 王祥柱. 基于旁路的复杂器械分离经根管取出策略探索与疗效评价[J/OL]. 中华口腔医学研究杂志(电子版), 2025, 19(06): 369-377.
[5] 伍通美, 杨春燕. 胃癌异时性肝转移外科与转化治疗研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2026, 20(01): 78-82.
[6] 王龙, 张海翘, 黄勇, 李佳璇, 翟育豪, 尹杰, 张军. 胃韧带样纤维瘤两例报告并文献复习[J/OL]. 中华普外科手术学杂志(电子版), 2026, 20(01): 96-98.
[7] 丁小博, 陈洁, 王艳波. 人工智能在泌尿系结石诊治中的应用进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(01): 15-21.
[8] 李建雄, 杨诚, 贺慷, 薛康颐, 郭文彬, 陈明坤, 刘存东. 精索静脉曲张伴血栓形成两例报告[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(01): 114-116.
[9] 许鹏, 邓一鸣, 张兴超, 莫益鑫, 郑炯文, 陈春晓, 郭凯, 徐啊白. 广东省医学会泌尿外科疑难病例多学科会诊(第24期)——膀胱憩室癌[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(01): 117-122.
[10] 蔡建珊, 陈进宏. 同时性结直肠癌肝转移手术策略[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(06): 813-821.
[11] 吴哲境, 李敬东. ICG荧光成像引导下腹腔镜肝切除术治疗肝癌的安全性和有效性Meta分析[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(06): 852-859.
[12] 黄少坚, 梁汉标, 李清平, 唐善华, 李青妍, 李芷西, 黄灿, 王小振, 陈灿辉, 王恺, 李川江. 基于影像组学和临床特征构建肝癌新辅助/转化治疗后病理学完全缓解预测模型[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(06): 860-867.
[13] 赵灵芝, 石光英. 熊去氧胆酸联合瑞舒伐他汀治疗脂肪肝合并高脂血症患者的临床疗效研究[J/OL]. 中华临床医师杂志(电子版), 2025, 19(08): 589-593.
[14] 姜宇丰, 张睿, 闵红巍. 全关节置换术后异位骨化的研究进展[J/OL]. 中华临床医师杂志(电子版), 2025, 19(07): 526-531.
[15] 王春茂, 韩鸣, 王子彤. 局限期小细胞肺癌新辅助治疗后完全病理学缓解五例[J/OL]. 中华临床医师杂志(电子版), 2025, 19(07): 550-554.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?